Table 2.
Patient Characteristics
| FLT3 mut | |||
|---|---|---|---|
| Variable | Wild type | Mut. | p-value |
| Number of pts | 353 | 158 | |
| Median Age(range) | 46 (18-60) | 47 (18-60) | 0.47 |
| Gender | 0.05 | ||
| Male | 190 (54) | 70 (44) | |
| Female | 163 (46) | 88 (56) | |
| Recipient race | 0.78 | ||
| Caucasian | 320 (91) | 142 (90) | |
| Non-Caucasian | 29 (8) | 15 (9) | |
| Karnofsky score | 0.92 | ||
| <90% | 103 (29) | 49 (31) | |
| ≥90% | 234 (66) | 102 (65) | |
| Missing | 16 (5) | 7 (4) | |
| White blood count at diagnosis (×10^9/L) | <0.001 | ||
| Median (range) | 10 (<1-344) | 34 (<1-305) | <0.001 |
| HCT Co-morbidity Index | 0.95 | ||
| 0 | 131 (37) | 57 (36) | |
| 1 | 91 (26) | 40 (25) | |
| 2+ | 10 (3) | 6 (4) | |
| Missing | 121 (34) | 55 (35) | |
| Cytogenetic abnormalities | <0.001 | ||
| Favorable | 25 (7) | 5 (3) | |
| Intermediate | 216 (61) | 128 (81) | |
| Normal | 114 (32) | 102(65) | |
| Poor | 101 (29) | 20 (13) | |
| Missing | 11 (3) | 5 (3) | |
| Disease status prior to HCT | 0.07 | ||
| CR1 | 252 (71) | 125 (79) | |
| CR2 | 101 (29) | 33 (21) | |
| Status at CR1 | <0.001 | ||
| Hematologic CR only | 123 (35) | 68 (43) | |
| Cytogenetic and molecular CR | 94 (27) | 64 (41) | |
| Cytogenetic CR | 130 (37) | 22 (14) | |
| Molecular CR | 6 (2) | 4 (3) | |
| Time from diagnosis to HCT (for CR1 HCT), months | 0.82 | ||
| Median (range) | 4 (2-17) | 4 (2-19) | 0.59 |
| <6 months | 199 (79) | 100 (80) | |
| ≥6 months | 53 (21) | 25 (20) | |
| Time to achieve CR1 (for CR1 HCT), weeks | 0.05 | ||
| Median (range) | 6 ( 1-71) | 5 (1-22) | 0.07 |
| Time from CR1 to HCT (for CR1 HCT), weeks | 0.12 | ||
| Median (range) | 11 (1-53) | 13 (1-76) | 0.02 |
| Lines of induction prior to CR1 (for CR1 HCT) | 0.06 | ||
| 1 | 177 (70) | 102 (82) | |
| 2 | 63 (25) | 20 (16) | |
| ≥3 | 12 (5) | 3 (2) | |
| Type of induction therapy (for CR1 HCT) | 0.12 | ||
| 7+3 | 156 (62) | 72 (58) | |
| 7+3 + other | 78 (31) | 50 (40) | |
| Other | 16 (6) | 3 (2) | |
| Cycle of consolidation therapy prior to CR1 HCT | 0.02 | ||
| No consolidation given | 86 (34) | 24 (19) | |
| 1 | 71 (28) | 49 (39) | |
| 2 | 32 (13) | 23 (18) | |
| ≥3 cycles | 33 (13) | 17 (14) | |
| Missing | 30 (12) | 12 (10) | |
| Duration of CR1 (for CR2 HCT), months | 0.006 | ||
| Median (range) | 11 (1-98) | 6 (<1-42) | 0.006 |
| Time from relapse to HCT (for CR2 HCT), months | 0.59 | ||
| Median (range) | 3 ( 1-17) | 3 (1-19) | 0.76 |
| 0-3 months | 41 (41) | 14 (42) | |
| 3-6 months | 43 (43) | 13 (39) | |
| >6 months | 9 (9) | 5 (15) | |
| Missing | 8 (8) | 1 (3) | |
| Conditioning regimen intensity | 0.19 | ||
| MAC with TBI | 140 (40) | 74 (47) | |
| MAC without TBI | 162 (46) | 62 (39) | |
| RIC/NMA | 51 (14) | 21 (13) | |
| Type of donor | 0.69 | ||
| HLA-identical sibling | 150 (42) | 67 (42) | |
| 8/8 URD | 165 (47) | 70 (44) | |
| 7/8 URD | 38 (11) | 21 (13) | |
| Donor age of unrelated donor HCT | 0.19 | ||
| Median (range) | 30 (19-56) | 33 (19-52) | 0.04 |
| GVHD prophylaxis | 0.75 | ||
| Tacrolimus ± others | 302 (86) | 139 (88) | |
| CSA ± others | 42 (12) | 16 (10) | |
| Others | 9 (3) | 3 (2) | |
| In vivo T cell Depletion | 0.84 | ||
| ATG alone | 80 (23) | 34 (22) | |
| Alemtuzumab alone | 4 (1) | 1 (<1) | |
| No ATG or alemtuzumab | 268 (76) | 123 (78) | |
| Graft type | 0.33 | ||
| Bone marrow | 59 (17) | 21 (13) | |
| Peripheral blood | 294 (83) | 137 (87) | |
| Donor/Recipient CMV serostatus | 0.60 | ||
| R+ | 193 (55) | 96 (61) | |
| R-D+ | 46 (13) | 16 (10) | |
| R-D− | 108 (31) | 44 (28) | |
| Donor/Recipient sex match | 0.16 | ||
| M/M | 121 (34) | 43 (27) | |
| M/F | 93 (26) | 56 (35) | |
| F/M | 69 (20) | 27 (17) | |
| F/F | 70 (20) | 32 (20) |
CSA: cyclosporine; ATG: anti-thymocyte globulin; CMV: cytomegalovirus